Sexual dysfunction affects an estimated 43 percent of women and 31 percent of men in the United States (Laumann et al., Journal of the American Medical Association). It is one of the most underdiscussed and undertreated conditions in medicine — and one of the largest opportunities in telehealth.
PT-141 (bremelanotide) is a peptide with FDA approval for female sexual dysfunction and off-label use for men. It works differently from every other sexual wellness drug on the market, which gives it a distinct clinical and commercial advantage. This guide explains how to build a telehealth brand around it.
What Makes PT-141 Different
Every well-known erectile dysfunction and libido drug — Viagra, Cialis, Addyi — works at the level of blood flow or hormones. PT-141 works at the level of the brain.
PT-141 is a melanocortin receptor agonist. It acts on MC3R and MC4R receptors in the hypothalamus, which are directly involved in regulating sexual desire and arousal at the neurological level. The result is endogenous arousal — the body’s own desire response — rather than mechanical or hormonal augmentation.
This has several commercial advantages:
- It works for both men and women through the same mechanism
- It helps patients who do not respond to PDE5 inhibitors (Viagra, Cialis)
- It has FDA approval for premenopausal women with HSDD as Vyleesi, providing a strong clinical credibility anchor
- The onset is 45 to 90 minutes and effects last 6 to 12 hours, fitting natural use patterns better than medications requiring daily dosing
The Sexual Wellness Market Opportunity
The global sexual health market was valued at $30 billion in 2022 and is projected to reach $52 billion by 2030 (Grand View Research). Within telehealth, men’s health brands (Hims, Roman, Keeps) have demonstrated that patients will pay monthly subscriptions for sexual health treatments delivered discreetly by mail.
The women’s side of this market is far less developed, creating a significant opportunity for brands focused on female sexual wellness. PT-141’s FDA approval for HSDD in women is a legitimate clinical anchor that very few telehealth products can claim.
Who You Are Building This Brand For
A PT-141 telehealth brand targets several overlapping demographics:
Women with HSDD or low libido. The primary FDA-approved indication. Women who feel their desire has diminished — whether from stress, hormonal shifts, relationship changes, or age — and want a clinically validated solution.
Perimenopausal women. Hormonal changes in perimenopause frequently cause significant libido decline. A brand focused on this audience can combine PT-141 with hormone optimization content and services.
Men seeking an alternative to PDE5 inhibitors. Men with cardiovascular conditions that contraindicate Viagra and Cialis, men who find those drugs produce unwanted side effects, or men who want a neurological rather than mechanical approach to sexual performance.
Couples. PT-141 is uniquely positioned for couples’ wellness marketing because both partners can use it. A “his and hers” brand approach is uncommon in telehealth and highly differentiated.
Building the Brand
A PT-141 telehealth brand under a turnkey platform looks like this:
- Patients complete a confidential online health assessment
- A licensed physician evaluates each patient and prescribes PT-141 if appropriate
- A 503A compounding pharmacy compounds and ships PT-141 subcutaneous injections
- The operator manages the brand, the audience, and the patient relationship
The brand layer is where you differentiate: your name, your visual identity, your content approach, and the audience you serve. The clinical infrastructure is provided by the platform.
Revenue structure:
- Program price: $149 to $249 per month (dose-dependent)
- Platform and pharmacy cost: $60 to $80 per patient per month
- Operator net: $70 to $110 per patient per month
Marketing a Sexual Wellness Brand Compliantly
Sexual wellness advertising has more restrictions than most health verticals. Platform policies on Meta, TikTok, and Google prohibit explicit content and often restrict sexual health claims.
Strategies that work:
Organic content focusing on emotional outcomes. Content about confidence, connection, relationship quality, and feeling like yourself again resonates strongly and avoids policy issues. The clinical specifics live on the website; the content feeds awareness and aspiration.
Influencer and community partnerships. Creators in women’s health, relationships, and perimenopause spaces have audiences that are directly addressable. These partnerships often outperform paid ads for sexual wellness brands.
Email and SMS retention. Once a patient is acquired, high-quality educational content about sexual health, lifestyle optimization, and the science of PT-141 drives long retention.
SEO content targeting clinical searches. Articles about “low libido treatment for women,” “PT-141 for women,” “bremelanotide,” and similar terms attract high-intent patients who are actively researching solutions.
Compliance Essentials
FTC requirements. Sexual health claims must be substantiated. Patient testimonials require proper disclosure. Claims about sexual performance improvement must reflect typical patient outcomes or include appropriate qualification.
FDA drug marketing rules. As a prescription product, PT-141 cannot be marketed as a drug to consumers without following prescription drug advertising rules. Marketing should emphasize the program (physician-supervised sexual wellness care) rather than the drug.
HIPAA. Patient health information collected through intake forms, patient portals, and communications must be handled under a HIPAA-compliant infrastructure. Your platform partner provides this.
Why Now
The sexual wellness telehealth market is growing rapidly but is still dominated by men’s health brands. The women’s side is years behind in brand development and patient education. A PT-141 brand focused on women’s desire and sexual wellness is targeting a large, motivated audience with limited direct competition and a medically validated product.
Book a call with Karpa Health to explore launching a PT-141 sexual wellness brand.
For more context on closely related topics, read Melanotan II guide, peptide therapy legal guide, and telehealth peptide prescribing guide.